MEREO BIOPHARMA GROUP PLC (MREO) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased its American Depositary Shares during the specified class period, alleging misleading information regarding clinical study results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Mereo ADS from June 5, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against Mereo - The complaint states that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell from $2.31 on December 26, 2025, to $0.29 on December 29, resulting in a loss of over 87.7% of its value in one day [3].